Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

Failure of Alzheimer's drug Dimebon: Anavex Life Sciences comments

Anavex Life Sciences Corp. today issued a statement following today's announcement from Pfizer and Medivation (MDVN) that their investigational Alzheimer's drug Dimebon did not meet either its co-primary or secondary endpoints compared to placebo during pivotal Phase 3 clinical trials.

4 Mar 2010

New chemical classes of preclinical compounds identified for Alzheimer’s disease

In an announcement today, Mount Sinai School of Medicine and Medisyn Technologies, Inc. said they have identified new chemical classes of preclinical compounds that may eventually lead to the first effective management of toxic amyloid aggregation and accumulation in the brain— an abnormal biological process long suspected by many researchers to be a major culprit in the onset and progression of Alzheimer’s disease.

4 Mar 2010

Negative results from latrepirdine Phase III clinical trial: Alzheimer's Association disappointed

"The Alzheimer's Association is disappointed to learn of the negative results from the Phase III clinical trial of latrepirdine (Dimebon)," said William Thies, Ph.D., Alzheimer's Association Chief Medical and Scientific Officer. "People with Alzheimer's, their families and caregivers desperately need more and better treatment options for this devastating, fatal brain disease."

4 Mar 2010

Study indicates ocular shingles may increase stroke risk

Having a shingles infection that affects the eyes may increase the risk of stroke, according to new research published in the March 3, 2010, online issue of Neurology®, the medical journal of the American Academy of Neurology.

4 Mar 2010

NAEC elects Mayo Clinic as top epilepsy treatment center

Mayo Clinic has been designated a comprehensive epilepsy treatment center by the National Association of Epilepsy Centers (NAEC). Only the top epilepsy programs - those that can provide the most complex and advanced care - are selected for this designation, according to the association.

3 Mar 2010

Researchers launch new project to diagnose and treat dementia among Deaf people who use BSL

Researchers have launched a unique project to improve early diagnosis and management of dementia among Deaf people who use British Sign Language (BSL).

From The University of Manchester 3 Mar 2010

Pfizer, Medivation announce results of two dimebon Phase 3 trials in AD patients

Pfizer Inc. and Medivation, Inc. today announced results from two Phase 3 trials of the investigational drug dimebon (latrepirdine) in patients with Alzheimer’s disease (AD). In the CONNECTION trial, dimebon did not meet its co-primary or secondary efficacy endpoints compared to placebo. Co-primary endpoints were measures of cognition and global function.

3 Mar 2010

Adult day health programs help senior participants maintain their health and independence

A recent study by San Francisco’s Institute on Aging documents that adult day health programs play a vital role in helping senior participants maintain their health and independence. Since the 1970s, adult day health care has been promoted as an alternative to nursing home care for seniors with chronic illness, disability, or dementia.

3 Mar 2010

Investigators use ANNs to recognize risk factors of AD in patients with MCI

Mild cognitive impairment (MCI) is often considered an early symptom of Alzheimer's disease (AD). An analysis of genetic risk factors predisposing to MCI is critical for accessing individual predisposition and reliably evaluating the effectiveness of early treatment. In a groundbreaking study published in the February 2010 issue of the Journal of Alzheimer's Disease investigators successfully used artificial neural networks (ANNs) to help understand the causal relation between multiple factors and the occurrence of neurodegenerative disorders.

3 Mar 2010

Pioneering stem cell research could revolutionize treatments for diabetes and Alzheimer's disease

A heart patient's own skin cells soon could be used to repair damaged cardiac tissue thanks to pioneering stem cell research of the University of Houston's newest biomedical scientist, Robert Schwartz.

3 Mar 2010

Sea squirts help in fight against Alzheimer's disease

Alzheimer's disease affects an estimated 27 million people worldwide. It is the most common form of age-related dementia, possibly the most feared disease of old age. There is no cure, and the available drugs only help to relieve symptoms without slowing progression of the disease. One of the characteristic changes in the brains of Alzheimer's patients is the accumulation of plaques and tangles; currently, the best hope for curing or at least slowing the disease lies in developing drugs that target this buildup.

2 Mar 2010

Clot-busting drug therapy after stroke beneficial for women

New research shows women who don't receive a clot-busting drug after a stroke fare worse than men who are not treated. The study is published in the March 2, 2010, print issue of Neurology®, the medical journal of the American Academy of Neurology.

2 Mar 2010

Causal relation between multiple factors and occurrence of neurodegenerative disorders: ANNs help understand better

2 Mar 2010

Individuals having greater purpose in lives less likely to develop Alzheimer's disease: Study

Individuals who report having greater purpose in their lives appear less likely to develop Alzheimer's disease or its precursor, mild cognitive impairment, according to a report in the March issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

2 Mar 2010

$28M grant to examine neural and behavioral profiles of healthy cognitive aging

The Research Partnership in Cognitive Aging, a public-private effort to promote the study of brain function with age, will award up to $28 million over five years to 17 research grants to examine the neural and behavioral profiles of healthy cognitive aging and explore interventions that may prevent, reduce or reverse cognitive decline in older people.

2 Mar 2010

Oxidative stress could lead to health problems and premature death

If you aren't getting a good, consistent and regular night's sleep, a new study suggests it could reduce your ability to handle oxidative stress, cause impacts to your health, increase motor and neurological deterioration, speed aging and ultimately cut short your life.

2 Mar 2010

Researchers uncover new explanation for the spread of tau protein within human brain

A team of researchers at UMass Lowell has found a new mechanism by which a key protein associated with Alzheimer's disease can spread within the human brain.

2 Mar 2010

Researchers proceed to develop vaccination to reverse neurological damage seen with Parkinson's disease

Researchers at the University of Nebraska Medical Center have taken a significant step forward in developing a vaccination approach to reverse the neurological damage seen with Parkinson's disease.

2 Mar 2010

Habits of modern life may shorten life-span of the Millennium Generation

All parents dream of a better life for their children, but because of the habits of modern life, the Millennium Generation may be the first to suffer a shorter life-span.

1 Mar 2010

[11C]PiB PET neuroimaging exhibits potential for monitoring therapeutics on amyloid beta load during Alzheimer’s disease treatment

Elan Corporation, plc today announced that findings from a Phase II study which suggested bapineuzumab reduced amyloid-beta deposits in the brains of Alzheimer’s disease patients as measured using a neuroimaging technique known as [11C]PiB PET, were published in the February 28, 2010 online edition of Lancet Neurology. Bapineuzumab is a compound under development by Pfizer and Janssen Alzheimer Immunotherapy, a Johnson & Johnson subsidiary in which Elan holds a minority equity interest.

1 Mar 2010

Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

Failure of Alzheimer's drug Dimebon: Anavex Life Sciences comments

New chemical classes of preclinical compounds identified for Alzheimer’s disease

Negative results from latrepirdine Phase III clinical trial: Alzheimer's Association disappointed

Study indicates ocular shingles may increase stroke risk

NAEC elects Mayo Clinic as top epilepsy treatment center

Researchers launch new project to diagnose and treat dementia among Deaf people who use BSL

Pfizer, Medivation announce results of two dimebon Phase 3 trials in AD patients

Adult day health programs help senior participants maintain their health and independence

Investigators use ANNs to recognize risk factors of AD in patients with MCI

Pioneering stem cell research could revolutionize treatments for diabetes and Alzheimer's disease

Sea squirts help in fight against Alzheimer's disease

Clot-busting drug therapy after stroke beneficial for women

Causal relation between multiple factors and occurrence of neurodegenerative disorders: ANNs help understand better

Individuals having greater purpose in lives less likely to develop Alzheimer's disease: Study

$28M grant to examine neural and behavioral profiles of healthy cognitive aging

Oxidative stress could lead to health problems and premature death

Researchers uncover new explanation for the spread of tau protein within human brain

Researchers proceed to develop vaccination to reverse neurological damage seen with Parkinson's disease

Habits of modern life may shorten life-span of the Millennium Generation

[11C]PiB PET neuroimaging exhibits potential for monitoring therapeutics on amyloid beta load during Alzheimer’s disease treatment

Aneuro: A Year of Neuroscience in Review eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

Aneuro: A Year of Neuroscience in Review eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in